X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Taiwan approved sNDA for Xofluza (baloxavir marboxil) for the treatment and postexposure prophylaxis for influenza virus infection for paediatrics aged 5 to <12 years.
Lead Product(s): Baloxavir Marboxil
Therapeutic Area: Infections and Infectious Diseases Product Name: Xofluza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
Fetroja (cefiderocol) for injection is the first and only siderophore cephalosporin antibiotic. It is being evaluated for the treatment of complicated urinary tract infections & Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Lead Product(s): Cefiderocol sulfate tosylate
Therapeutic Area: Infections and Infectious Diseases Product Name: Fetroja
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
The joint venture will initially focus on accelerating the discovery, preclinical and clinical development of novel pharmacologic solutions designed to address the complex pathology of obstructive sleep apnea.
Lead Product(s): Undisclosed
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Apnimed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 31, 2023
Details:
Under the agreement, the 7 selected generic manufacturers will manufacture and supply Xocova (ensitrelvir fumaric acid), an oral antiviral drug for COVID-19 recently approved in Japan, in 117 low and middle income countries.
Lead Product(s): Ensitrelvir Fumaric Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: Xocova
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Charioteer
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 26, 2023
Details:
Through the acquisition, Shionogi extends its infectious disease innovation platform with the access to a novel investigational beta-lactamase inhibitor, QPX7728 (xeruborbactam), which is being advanced clinically for infections caused by drug-resistant Gram-negative bacteria.
Lead Product(s): Xeruborbactam,QPX2015
Therapeutic Area: Infections and Infectious Diseases Product Name: QPX7728
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Qpex Biopharma
Deal Size: $140.0 million Upfront Cash: $100.0 million
Deal Type: Acquisition June 25, 2023
Details:
S-217622 (ensitrelvir), known as Xocova® 125 mg tablet, approved in Japan. Ensitrelvir is an oral antiviral agent administered once daily for five days that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
Lead Product(s): Ensitrelvir Fumaric Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: S-217622
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
Under the terms of the collaboration, Shionogi, Nagasaki University and MMV will accelerate the evaluation and the development of new drugs for the treatment of malaria.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Nagasaki University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 13, 2023
Details:
The funding will be used to accelerate the evaluation and the development of new drugs for the treatment of malaria by Shionogi, Nagasaki University and MMV.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: GHIT Fund
Deal Size: $0.9 million Upfront Cash: Undisclosed
Deal Type: Funding March 13, 2023
Details:
Xocova® (ensitrelvir fumaric acid) is an antiviral drug for COVID-19 which suppresses the replication of SARS-CoV-2 by selectively inhibiting 3CL protease.
Lead Product(s): Ensitrelvir Fumaric Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: Xocova
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
S-268019 is a recombinant protein-based preventive vaccine, for use in priming and booster (3rd) doses, against COVID-19, caused by the novel coronavirus (SARS-CoV-2) infection.
Lead Product(s): S-268019
Therapeutic Area: Infections and Infectious Diseases Product Name: S-268019
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
